The effect of tDCS on Opioid patients under methadone maintenance treatment

The effect of Transcranial Direct Current Stimulation(tDCS) on craving, relaps and mental health parameters in Opioid patients under methadone maintenance treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180604039979N1

Enrollment

Registered

2018-06-18

Start date

2018-06-11

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Addiction. Condition 2: Addiction. Opioid abuse with opioid-induced mood disorder Opioid abuse with opioid-induced sleep disorder

Interventions

Intervention 1: Intervention group: 7 sessions and receive tDCS electrical stimulation every two days. This electrical stimulation by the tDCS device at 2 mAh for 20 minutes will be a right and left /

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Detection of drug abuse and dependence on opioids under methadone maintenance treatment according to DSM-V diagnostic criteria by a specialist psychiatrist The patient only receives methadone treatment Methadone maintenance treatment for at least one year Have at least 9th grade literacy Complete informed consent Aged 18-60 years

Exclusion criteria

Exclusion criteria: Having any progressive disease, such as diabetes and neurological diseases, especially a history of head truma and seizure Having metal objects or prostheses in head Having a shunt on the skull and pacemaker in the heart The presence of severe psychiatric illnesses in the I axis based on DSM-V diagnostic criteria: such as psychotic disorders Taking other medicines in addition to methadone (such as morphine, hashish, glass) Unwilling to participate in research

Design outcomes

Primary

Measure	Time frame
Reduce craving. Timepoint: Fourth and seventh session of intervention. Method of measurement: desire for drug questionnaire(DDQ).;Reduce relaps. Timepoint: Fourth and seventh session of intervention. Method of measurement: Urine test.;Reduce depression. Timepoint: Fourth and seventh session of intervention. Method of measurement: Depression, Anxiety and stress Scales (DASS-21).;Reduce anxiety. Timepoint: Fourth and seventh session of intervention. Method of measurement: Depression, Anxiety and stress Scales(DASS-21).;Reducing stress. Timepoint: Fourth and seventh session of intervention. Method of measurement: Depression, Anxiety and stress Scales(DASS-21).;Sleep quality. Timepoint: Fourth and seventh session of intervention. Method of measurement: Pittsburgh Sleep Quality Index(PSQI).	—

Measure

Time frame

Reduce craving. Timepoint: Fourth and seventh session of intervention. Method of measurement: desire for drug questionnaire(DDQ).;Reduce relaps. Timepoint: Fourth and seventh session of intervention. Method of measurement: Urine test.;Reduce depression. Timepoint: Fourth and seventh session of intervention. Method of measurement: Depression, Anxiety and stress Scales (DASS-21).;Reduce anxiety. Timepoint: Fourth and seventh session of intervention. Method of measurement: Depression, Anxiety and stress Scales(DASS-21).;Reducing stress. Timepoint: Fourth and seventh session of intervention. Method of measurement: Depression, Anxiety and stress Scales(DASS-21).;Sleep quality. Timepoint: Fourth and seventh session of intervention. Method of measurement: Pittsburgh Sleep Quality Index(PSQI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad sadeghi bimorgh

Kashan University of Medical Sciences

sadeghi6637@yahoo.com+98 51 3604 9454

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026